{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:39:46Z","timestamp":1777887586539,"version":"3.51.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bone marrow hemodilution could compromise next generation flow cytometry based measurable residual disease evaluation in multiple myeloma and may cause false negative results. This review summarizes definitions, markers, indices, mitigation strategies, and current challenges in standardization.<\/jats:p>","DOI":"10.3389\/fonc.2026.1849714","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:17:59Z","timestamp":1777609079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review"],"prefix":"10.3389","volume":"16","author":[{"given":"Sorina Nicoleta","family":"Badelita","sequence":"first","affiliation":[{"name":"Department of Hematology, Fundeni Clinical Institute","place":["Bucharest, Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horia Mihail","family":"Sandu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundeni Clinical Institute","place":["Bucharest, Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundeni Clinical Institute","place":["Bucharest, Romania"]},{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy","place":["Bucharest, Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia Codruta","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundeni Clinical Institute","place":["Bucharest, Romania"]},{"name":"Department of Pediatrics, \u201cCarol Davila\u201d University of Medicine and Pharmacy","place":["Bucharest, Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S918","DOI":"10.1016\/S2152-2650(25)02600-X","article-title":"MM-403: albumin\/fibrinogen ratio (AFR) and red cell distribution width (RDW) as prognostic markers in multiple myeloma (MM)","volume":"25","author":"Rostom","year":"2025","journal-title":"Clin Lymph Myel Leuk"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135\u20135","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S781","DOI":"10.1016\/j.annonc.2021.08.139","article-title":"846P predictive and prognostic values of serum VEGF in patients with multiple myelomas receiving bortezomib-based therapy","volume":"32","author":"Khallaf","year":"2021","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236\u20133","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1057713","article-title":"Friends and foes\u201d of multiple myeloma measurable\/minimal residual disease evaluation by next generation flow","volume":"12","author":"Pacelli","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.04.010","article-title":"Bone marrow harvest: a white paper of best practices by the NMDP Marrow Alliance","volume":"30","author":"Murakami","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.101054","article-title":"Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards: cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes","volume":"26","author":"Akkari","year":"2024","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04249\u20132","article-title":"Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response","volume":"99","author":"Demyanets","year":"2020","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cyto.b.22053","article-title":"Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis","volume":"102","author":"Soh","year":"2022","journal-title":"Cytom B Clin Cytom"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13100320","article-title":"Applications of multiparameter flow cytometry in the diagnosis, prognosis, and monitoring of multiple myeloma patients","volume":"13","author":"Leonardos","year":"2025","journal-title":"Diseases"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071704","article-title":"B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients","volume":"13","author":"Mendon\u00e7a de Pontes","year":"2021","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma","volume":"23","author":"Foureau","year":"2023","journal-title":"Clin Lymph Myel Leuk"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072060","article-title":"Consensus for flow cytometry clinical report on multiple myeloma: a multicenter harmonization process merging laboratory experience and clinical needs","volume":"15","author":"Cordone","year":"2023","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B22","article-title":"A method for quantification of peripheral blood admixture in bone marrow aspirates","volume":"8","author":"Holdrinet","year":"1980","journal-title":"Exp Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cyto.b.20439","article-title":"Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination","volume":"76","author":"Brooimans","year":"2009","journal-title":"Cytom B Clin Cytom"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22225","article-title":"Focus on the Holdrinet index: toward blast quantification by flow cytometry","volume":"108","author":"Bonneville","year":"2025","journal-title":"Cytom B Clin Cytom"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04\u2013347484","article-title":"Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells","volume":"120","author":"Bruns","year":"2012","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30257","article-title":"Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis","volume":"139","author":"Wilk","year":"2016","journal-title":"Int J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21643","article-title":"Accurate quantification of fourteen normal bone marrow cell subsets in infants to the elderly by flow cytometry","volume":"94","author":"Pont","year":"2018","journal-title":"Cytom B Clin Cytom"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1001048","article-title":"The ALLgorithMM: how to define the hemodilution of bone marrow samples in lymphoproliferative diseases","volume":"12","author":"Vigliotta","year":"2022","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates","volume":"442","author":"Delgado","year":"2017","journal-title":"J Immunol Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18\u20131597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403680","article-title":"Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome","volume":"19","author":"Malcovati","year":"2005","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(96)00197-7","article-title":"Immunophenotypic analysis of myelodysplastic syndromes","volume":"88","author":"Del Ca\u00f1izo","year":"2003","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41408-023-00951\u20132","article-title":"Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: proposal for a bone marrow quality index","volume":"13","author":"\u00d3skarsson","year":"2023","journal-title":"Blood Cancer J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70076","article-title":"Enhanced detection of multiple myeloma cells by next-generation flow cytometry following density gradient medium separation","volume":"116","author":"O\u2019Brien","year":"2026","journal-title":"Eur J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.5378.5378","article-title":"CD33 is expressed in a significant subset of multiple myeloma patients in the US and may represent a viable therapeutic target","volume":"130","author":"Levy","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029234","article-title":"Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment","volume":"146","author":"Lasa","year":"2025","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21862","article-title":"Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease","volume":"98","author":"Soh","year":"2020","journal-title":"Cytom B Clin Cytom"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206\u20136","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23372","article-title":"Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: a case study","volume":"34","author":"Zhang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194937","article-title":"Flow cytometric analysis of bone marrow particle cells for measuring minimal residual disease in multiple myeloma","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01017-x","article-title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","volume":"22","author":"Paiva","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives","volume":"9","author":"Romano","year":"2019","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24686","article-title":"Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: the Cinderella method","volume":"103","author":"Hoffmann","year":"2023","journal-title":"Cytom Part J Int Soc Anal Cytol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:18:00Z","timestamp":1777609080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1849714"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1849714","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1849714"}}